Press Releases

2017.10.17 R&D PDF (90KB)
Daiichi Sankyo Announces Support by the Japan Agency for Medical Research and Development’s CiCLE Program for Its Collaborative Research with Saitama Medical University on Fibrodysplasia Ossificans Progressiva, and Commencement of an Industry-Government-Academia Research & Development Collaboration for Development of Therapies Using the Research
2017.10.16 R&D PDF (91KB)
Commencement of Collaborative Research on Measurement of Exosomes in Blood from Cancer Patients
2017.10.12 R&D PDF (88KB)
Daiichi Sankyo Announces Support from the Japan Agency for Medical Research and Development’s CiCLE Program for Its Genetic Vaccine Platform, and Commencement of an Industry- Government-Academia Research & Development Collaboration for Development Vaccines Using the Platform
2017.10.11 R&D PDF (80KB)
Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library
2017.10.06 Corporate PDF (105KB)
Daiichi Sankyo to Install Call Center Support System in Japan Utilizing Artificial Intelligence
2017.09.29 Corporate PDF (98KB)
Daiichi Sankyo Underwrites All Shares Issued by Kitasato Daiichi Sankyo Vaccine
2017.09.26 R&D PDF (119KB)
Daiichi Sankyo Announces TaNeDS Global 2018 Collaborative Drug Discovery Program
2017.09.25 R&D PDF (147KB)
Daiichi Sankyo Initiates Pivotal Phase 3 study in Japan of Esaxerenone in Patients with Diabetic Nephropathy
2017.09.25 R&D PDF (121KB)
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Study in Japan of Esaxerenone for Treatment of Essential Hypertension
2017.09.15 CSR PDF (114KB)
Daiichi Sankyo Listed on the Dow Jones Sustainability Indices World Index
2017.09.15 Corporate PDF (262KB)
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
2017.09.12 R&D PDF (68KB)
Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
2017.09.07 Products PDF (48KB)
Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent
2017.09.07 R&D PDF (68KB)
Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers
2017.09.07 Corporate PDF (106KB)
Daiichi Sankyo Announces Organizational Restructuring Effective as of October 1, 2017
2017.09.01 Products PDF (128KB)
Restriction on prescription period lifted for antiepileptic VIMPAT® Tablets 50 mg and 100 mg
2017.08.31 Corporate PDF (98KB)
Announcement regarding today’s media report
2017.08.31 R&D PDF (84KB)
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain
2017.08.31 Corporate PDF (102KB)
Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108
2017.08.30 R&D PDF (46KB)
Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer
2017.08.30 R&D PDF (45KB)
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer
2017.08.29 R&D PDF (399KB)
Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers
2017.08.29 Corporate PDF (63KB)
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitorfor Solid Tumors
2017.08.28 Local (JPN) PDF (88KB)
Daiichi Sankyo Announces New Oxycodone Tablets "Daiichi Sankyo" for Cancer Pain Treatment in Japan
2017.08.25 Local (JPN) PDF (108KB)
Daiichi Sankyo Obtains Approval in Japan for Additional Indication and Dosage for Ovisot® for Injection in Diagnosis of Vasospastic Angina
2017.08.25 Products PDF (131KB)
Antiepileptic VIMPAT® Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients
2017.08.07 R&D PDF (109KB)
Daiichi Sankyo Invests in Osaka University Spin-Off Venture with the Aim of Commercializing iPS-derived Cardiomyocyte Sheet
2017.08.07 Corporate PDF (92KB)
Daiichi Sankyo to Collaborate on Commercialization of Generic Transdermal Fentanyl Citrate Patches for Long-Acting Cancer Pain Relief
2017.08.02 Corporate PDF (97KB)
Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation
2017.07.20 R&D PDF (86KB)
Daiichi Sankyo Opens Applications for Investigator-Initiated Studies Program
2017.07.19 R&D PDF (43KB)
Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration
2017.07.18 Corporate PDF (95KB)
Daiichi Sankyo Announces Completion of Payment Concerning Disposal of Treasury Shares as Restricted Share-Based Remuneration
2017.07.12 Corporate PDF (51KB)
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
2017.07.11 R&D PDF (190KB)
Oncolytic Virus G47Δ (DS-1647) designated as Orphan Drug under Orphan Drug/Medical Device Designation System
2017.07.11 CSR PDF (77KB)
Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell
2017.07.05 R&D PDF (88KB)
Daiichi Sankyo Announces Discontinuation of Etanercept Biosimilar (CHS-0214) Development in Japan
2017.07.03 Products PDF (41KB)
Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Application approved in Japan for CANALIA® Combination Tablets, a type 2 diabetes mellitus treatment agent
2017.07.03 Products PDF (136KB)
Daiichi Sankyo Obtains Approval for Additional Indication for PRALIA® Subcutaneous Injection 60mg Syringe
2017.07.03 CSR PDF (86KB)
15th Takamine Memorial Daiichi Sankyo Prize Winner Announced
2017.06.30 R&D PDF (87KB)
Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes
2017.06.19 Products PDF (84KB)
Daiichi Sankyo Announces Launch of Narurapid® Tablets and Narusus® Tablets for Cancer Pain Treatment
2017.06.19 Corporate PDF (140KB)
Daiichi Sankyo Announces Disposal of Treasury Shares as Restricted Share-Based Remuneration
2017.06.16 CSR PDF (92KB)
Daiichi Sankyo’s Japan Research Foundation for Clinical Pharmacology 10th Annual Clinical Pharmacology Research Award
2017.06.15 Local (JPN) PDF (1,008KB)
Daiichi Sankyo Launches New Generic Drugs through Its Daiichi Sankyo Espha Subsidiary
2017.06.06 R&D PDF (48KB)
New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
2017.05.31 Products PDF (148KB)
Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce Plans for Commercialization of RoxyBond™ (oxycodone hydrochloride) Tablets CII in the U.S.
2017.05.11 Corporate PDF (128KB)
Daiichi Sankyo Announces “Partial Amendment to the Articles of Incorporation” and “Election of a candidate for Member of the Audit and Supervisory Board”
2017.05.11 Corporate PDF (98KB)
Differences Between Consolidated Results for Fiscal 2016 and Fiscal 2015
2017.05.08 R&D PDF (100KB)
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation
2017.04.28 Corporate PDF (91KB)
Daiichi Sankyo Announces the Introduction of a Restricted Share-Based Remuneration Plan
2017.04.28 Corporate PDF (165KB)
Daiichi Sankyo Revises Fiscal 2016 Consolidated Forecasts and Announces Fiscal 2017 Consolidated Forecasts
2017.04.28 Corporate PDF (91KB)
Daiichi Sankyo Announces Impairment Loss Related to Kitasato Daiichi Sankyo Vaccine
2017.04.27 Corporate PDF (42KB)
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
2017.04.24 R&D PDF (89KB)
Daiichi Sankyo Announces Designation of Duchenne Muscular Dystrophy Treatment DS-5141 under “SAKIGAKE Designation System”
2017.04.04 Corporate PDF (48KB)
Daiichi Sankyo, Inc. Announces Sale of Pharmaceutical Packaging Plant in Bethlehem, PA
2017.03.31 R&D PDF (99KB)
Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
2017.03.30 Local (JPN) PDF (70KB)
Daiichi Sankyo Announces Manufacture and Sales Approval in Japan of Narurapid® Tablets and Narusus® Tablets for Cancer Pain Treatment
2017.03.30 Products PDF (15KB)
Daiichi Sankyo Submits Application for Additional Indication and Dosage for Ovisot® Intracoronary Injection 0.1g in Diagnosis of Vasospastic Angina
2017.03.30 Corporate PDF (33KB)
Daiichi Sankyo Announces Collaborative Research on Drugs for Neglected Tropical Diseases
2017.03.29 Local (JPN) PDF (62KB)
Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field
2017.03.23 R&D PDF (92KB)
Daiichi Sankyo to Facilitate New Drug Discovery in 2017 through Collaborative Research and Grants
2017.03.16 Corporate PDF (55KB)
The National Institutes of Biomedical Innovation, Health and Nutrition, Daiichi Sankyo,and Mitsubishi UFJ Capital Announce Open Innovation Research on New Cancer Immunotherapy
2017.03.13 R&D PDF (35KB)
Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism (VTE) in Cancer Patients
2017.03.13 Corporate PDF (41KB)
Daiichi Sankyo Enters Agreement with Heptares Therapeutics to Discover and Develop Novel, Small-Molecules for the Treatment of Pain
2017.03.08 Local (JPN) PDF (43KB)
Daiichi Sankyo Announces New Oxycodone Extended Release Tablets "Daiichi Sankyo" for Sustained Cancer Pain Treatment
2017.03.07 R&D PDF (98KB)
Daiichi Sankyo Initiates ENTRUST-AF PCI Study Investigating Once-Daily Lixiana® (edoxaban) in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stenting
2017.03.03 CSR PDF (73KB)
Winner of 2016 Manpei Suzuki International Prize for Diabetes Research Announced
2017.03.01 R&D PDF (149KB)
Commencement of Phase 1 Trial for the Mutant IDH1 Inhibitor (DS-1001) Targeting Malignant Brain Tumors
2017.02.24 Corporate PDF (85KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2017.02.24 Corporate PDF (97KB)
Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017
2017.02.22 Corporate PDF (15KB)
Daiichi Sankyo Joins “IkuBoss Alliance”
2017.02.20 R&D PDF (64KB)
Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
2017.02.15 Local (JPN) PDF (18KB)
Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha
2017.02.10 Corporate PDF (75KB)
Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure
2017.02.06 R&D PDF (55KB)
Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use
2017.02.02 CSR PDF (18KB)
Daiichi Sankyo Announces Continuation of Mobile Healthcare Field Clinic Service Aimed at Improving Healthcare Access in Tanzania
2017.01.31 Corporate PDF (29KB)
Daiichi Sankyo Announces New Chairman and President
2017.01.19 R&D PDF (44KB)
Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer
2017.01.18 CSR PDF (13KB)
Daiichi Sankyo Announces Participation in the Global Initiative, Access Accelerated
2017.01.10 Corporate PDF (21KB)
Daiichi Sankyo Announces Reorganization of Research & Development System
2017.01.10 Corporate PDF (17KB)
Daiichi Sankyo Establishes Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma

In order to view the PDF files, you need to have the latest version of Adobe Reader installed.